A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion

Inclusion Criteria: * Symptomatic vitreomacular adhesion (VMA) which, in the opinion of the Investigator, is related to decreased visual function; * Best corrected visual acuity (BCVA) of 20/25 or worse in the study eye; * BCVA of 20/800 or better in the non-study eye; * Provide written informed consent; * Follow specified instructions during study period; * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Evidence of proliferative retinopathy, exudative age-related macular degeneration, or retinal vein occlusion in the study eye; * Vitreous hemorrhage or other opacification; * High myopia in the study eye; * Ocular surgery, laser photocoagulation treatment, or intravitreal injection(s) in the study eye in the prior 3 months; * Uncontrolled glaucoma in the study eye; * History of retinal detachment in either eye; * Active infection in either eye; * Pregnant or of child-bearing potential and not utilizing acceptable form of contraception; * Participation in another investigational drug study within 30 days prior to this study; * Other protocol-defined exclusion criteria may apply.